Trial · NCT02729324
Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
NCT02729324, Phase 2, Unknown, Yun-fei Xia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT. Trials, record NCT02729324. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02729324
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
- NCT number
- NCT02729324
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 136 participants, estimated
- Lead sponsor
- Yun-fei Xia
- Conditions
- Nasopharyngeal Neoplasms, Radiodermatitis
- Interventions
- Medical Radiation Protectants (FORRAD®), Trolamine (Biafine)
- First posted
- 2016-04-06
- Last updated
- 2016-04-06
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of grade ≥ 3 radiation dermatitis | Day 56 after completion or termination of radiotherapy | Incidence of grade ≥ 3 radiation dermatitis according to CTCAE version 4.0 |
| Primary | The Skindex-16 | Day 56 after completion or termination of radiotherapy | The skindex-16 is an analogue scale of symptoms and functional endpoints related to skin toxicity that may occur in the radiation treatment area. The mean AUC of Skindex-16 score over time. Patients were asked to complete the Skindex-16 only in reference to the skin receiving RT. |
| Primary | The symptom experience diary (SED) | Day 56 after completion or termination of radiotherapy | The symptom experience diary (SED) required the patient to rate the severity of multiple skin toxicity-related signs and symptoms on a scale of 0 (do not experience) to 10 (experience all the time). |
| Primary | EORTC QLQ-C30 | Day 56 after completion or termination of radiotherapy | EORTC QLQ-C30 is a Quality-of-Life Instrument proposed by the European Organization for Research and Treatment of Cancer (EORTC), for use in International Clinical Trials in Oncology. The QLQ-C30 incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality-of-life scale. |
| Secondary | Interruption time during the schedule of radiotherapy | Through radiotherapy completion or termination, an average of 7 weeks | The cumulative interruption time during the schedule of radiotherapy because of grade 3 or higher radiation dermatitis. |
| Secondary | Time for healing of radiation dermatitis | Through study completion, an average of 15 weeks | Time until healing of radiation dermatitis, after the completion or the termination of radiotherapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02729324
GET https://conductscience.org/api/trials/v1/NCT02729324/registered